Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 6, 2013, Pages 3931-3936

  Shafaghi, Afshin ^a,b   Mansour Ghanaei, Fariborz ^a,b   Joukar, Farahnaz ^b   Sharafkhah, Maryam ^c   Mesbah, Alireza ^d   Askari, Kurosh ^a   Geranmayeh, Siamak ^e   Mehrvarz, Alireza ^f   Souti, Fatemeh ^a   Sokhanvar, Homayoon ^a,b   Fakhrieh, Saba ^a,b   Aminian, Keyvan ^a,b   Yousefi Mashhour, Mahmud ^a,b   Khosh Sorur, Mahmud ^b   Rasoulian, Javid ^b  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Razi Laboratory   (Iran)

^e Sina Medical Laboratory   (Iran)

^f Afrapathobiology Laboratory   (Iran)

Author keywords

Gastric cancer; Gastrin; Northern Iran; Pepsinogen I; Pepsinogen II; Preneoplastic lesion

Indexed keywords

EID: 84882701170     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.6.3931     Document Type: Article

References (31)

1. Axon A (2002). Gastric cancer and Helicobacter pylori. Aliment Pharmacol Ther, 16, 83-8.
2. Borch K, Axelsson CK, Halgreen H, et al (1989). The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis. Scand J Gastroenterol, 24, 870-6
3. Carneiro F, Machado JC, David L, (2001). Current thoughts on the histopathogenesis of gastric cancer. Eur J Cancer Prev, 10, 101-2.
4. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, et al (2004). Validity of serum Pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia, 6, 449-56.
5. Haj-Sheykholeslami A, Rakhshani N, Amirzargar A, et al (2008). Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol, 6, 174-9.
6. Iijima K, Abe Y, Kikuchi R, et al (2009). Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol, 15, 853-9.
7. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
8. Karnes WE Jr, Samloff IM, Siurala M, et al (1991). Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology , 101, 167-74
9. Kikuchi R, Abe Y, Iijima K, et al (2011). Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med, 223, 35-44.
10. Kitahara F, Kashiwagi A, Kanai T, et al (1996). A role of pepsinogen assay as the first cancer screening before screening by gastroscopy. J Gastroenterological Mass Survey, 116, 42-8.
11. Kitahara F, Kobayashi K, Sato T, et al (1999). Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut, 44, 693-7.
12. Kodoi A, Yoshihara M, Sumii K, et al (1995). Serum pepsinogen in screening for gastric cancer. J Gastroenterol, 30, 452-60.
13. Kwon YM, Lim HT, Lee K, et al (2009). Factors associated with use of gastric cancer screening services in Korea. World J Gastroenterol, 15, 3653-9.
14. Maconi G, Manes G, Porro GB (2008). Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol, 14, 1149-55.
15. Malekzadeh R, Derakhshan MH, Malekzadeh Z (2009).Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med, 12, 576-83.
16. Mansour-Ghanaei F, Joukar F, Soati F, Mansour-Ghanaei A, Bakhshizadeh Naserani S (2012). Knowledge about gastric carcinoma in North of Iran, a high prevalent region for gastric carcinoma: a population-based telephone survey. Asian Pac J Cancer Prev, 13, 3361-6.
17. Mansour-Ghanaei F, Sokhanvar H, Joukar F, et al (2010). Endoscopic findings in a mass screening program for cancer in a high risk region- Guilan province of Iran. Asian Pac J Cancer Prev, 13, 1407-12.
18. Miki K (2011). Gastric cancer screening by combined assay for serum anti-Helicobacter Gastric cancer screening by combined assay for serum anti-Helicobacter. Proc Jpn Acad Ser B Phys Biol Sci, 87, 405-14.
19. Miki K, Ichinose M, Ishikawa KB, et al (1993). Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res, 84, 1086-90.
20. Miki K (1992). Mass screening of stomach neoplasms by serum pepsinogen analysis. J Jpn Society of Internal Med, 81, 654-9.
21. Miki K, Ichinose M, Kawamura N, et al (1989). The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic a gastritis in Japanese subjects. Jpn J Cancer Res, 80, 111-14.
22. Nasrollahzade D, Aghcheli K, Sotoudeh M, et al (2011). Accuracy and cut-off values of pepsinogens I,II, and Gastrin 17 for diagnosis of gastric fundic atrophy: Influence of gastritis. PLoS one, 6, 26957.
23. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
24. Parkin DM (2004). International variation. Oncogene, 23, 6329-40.
25. Parkin DM, Bray FI, Devesa SS (2001). Cancer burden in the year 2000. The global picture. Eur J Cancer, 37, 4-66 .
26. Puri S, Mangat C, Bhatia V, Kaur AP, Kohli DR (2010). Knowledge of cancer and its risk factors in Chandigarh, India. Int J Epidemiol, 8, 1-7.
27. Sadjadi A, Malekzadeh R, Derakhshan MH, et al (2003). Cancer occurrence in Ardabil: results of a population-based cancer registry from Iran. Int J Cancer, 107, 113-8.
28. Sadjadi A, Nouraie M, Mohagheghi MA, et al (2005). Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev, 6, 359-63.
29. Stemmermann GN, Samloff IM, Nomura AM, et al (1987). Serum pepsinogens I and II and stomach cancer. Clin Chim Acta, 163, 191-8.
30. Varis K, Sipponen P, Laxen F, et al (2000). Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand J Gastroenterol, 35, 950-6.
31. Yanaoka K, Oka M, Mukoubayashi C, et al (2008). Cancer highrisk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev, 17, 838-45.